(1) Costs | (2) Savings | Net cost | Averted | Cost per | |||||
Total | Hepatitis C treatment | Cirrhosis and liver cancer treatment | Total | (1) minus (2) | Infection | Death | Infection averted | Death averted | |
Male | |||||||||
20–29 | 1 039 000 | 872 874 | 190 650 | 1 063 524 | −24 524 | 17.0 | 1.67 | −1440 | −14 680 |
30–39 | 1 039 000 | 856 106 | 299 994 | 1 156 100 | −117 100 | 17.7 | 3.48 | −6609 | −33 695 |
40–49 | 1 039 000 | 851 311 | 501 489 | 1 352 800 | −313 800 | 15.8 | 7.82 | −19 866 | −40 136 |
50–59 | 1 039 000 | 836 151 | 331 947 | 1 168 098 | −129 098 | 13.4 | 8.90 | −9606 | −14 500 |
60–69 | 1 039 000 | 778 178 | 207 695 | 985 874 | 53 126 | 11.1 | 11.21 | 4791 | 4737 |
70+ | 1 039 000 | 606 893 | 56 394 | 663 287 | 375 713 | 8.1 | 8.09 | 46 303 | 46 441 |
20+ | 1 039 000 | 812 871 | 311 702 | 1 124 573 | −85 573 | 13.6 | 8.14 | −6278 | −10,512 |
Female | |||||||||
20–29 | 1 039 000 | 844 363 | 18 545 | 862 908 | 176 092 | 19.1 | 0.23 | 9216 | 764 891 |
30–39 | 1 039 000 | 829 795 | 39 472 | 869 267 | 169 733 | 20.0 | 0.42 | 8492 | 399 695 |
40–49 | 1 039 000 | 818 503 | 95 966 | 914 469 | 124 531 | 21.0 | 1.17 | 5944 | 106 531 |
50–59 | 1 039 000 | 824 358 | 156 745 | 981 103 | 57 897 | 19.2 | 2.38 | 3022 | 24 323 |
60–69 | 1 039 000 | 802 704 | 207 761 | 1 010 464 | 28 536 | 16.9 | 3.90 | 1685 | 7326 |
70+ | 1 039 000 | 634 720 | 120 913 | 755 633 | 283 367 | 12.0 | 3.26 | 23 614 | 86 936 |
20+ | 1 039 000 | 758 304 | 141 486 | 900 666 | 138 334 | 16.5 | 2.76 | 8367 | 50 177 |
Table shows costs and consequences of placing an additional 100 individuals on treatment, evaluated around the status quo scenario. Costs of testing are subsumed under treatment costs, and it is assumed that 12 individuals are tested for each person progressing to treatment. All totals are through 2050, and we used the 2016 year-average exchange rate29 to convert Korean won to US dollars (KRW 1160) and a discount rate of 3%.30